Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance

PAPZIMEOS ® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 bringing launch-to-date net product revenue to $151 million, underscoring sustained commercial momentum and expanding US adoption Achieved positive cash flow in the third quarter of 2026, a full quarter ahead of guidance, driven by robust PAPZIMEOS uptake Net income for the third quarter of $35.8 million Cash, cash equivalents, and investments totaled $51.0 million as of September 30, 2026 Received FDA Platform Technology Designation for the AdenoVerse ® platform, creating opportunities to...